Online inquiry

IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3103MR)

This product GTTS-WQ3103MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FASLG gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000639.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 356
UniProt ID Q53ZZ1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3103MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8986MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ12406MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ8052MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ14294MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ14075MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ4086MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ6319MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ8300MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HM-12525A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW